Detailed Analysis of US Patent 7,150,881: Scope, Claims, and Patent Landscape
What is the scope of US Patent 7,150,881?
US Patent 7,150,881 pertains to a pharmaceutical composition comprising a specific antibody or fragment, designed for targeted therapy. The patent claims cover compositions, methods of production, and therapeutic applications involving these antibodies.
Patent Classification
- International Classification (IPC): A61K 39/00 (Medicinal preparations containing antigens or antibodies)
- Cooperative Patent Classification (CPC): A61K 39/00, C07K 16/00
Key Focus
- Targeted monoclonal antibodies
- Specific antigen-binding fragments
- Therapeutic methods for treating certain conditions
What are the main claims of the patent?
Core Claims
| Claim Type |
Content |
Scope |
| Independent Claims |
Claim 1 describes an antibody or fragment with specific binding affinity to a target antigen; Claim 15 details a method of producing the antibody; Claim 25 covers pharmaceutical compositions containing the antibody |
Broad coverage of the antibody's structure and production methods |
| Dependent Claims |
Refine the antibody's structure, specify certain sequences, or specify therapeutic uses |
Narrower scope, adding specific embodiments |
Significant Claims
- Claim 1: Antibody with an amino acid sequence that specifically binds to a designated antigen associated with disease X.
- Claim 15: A method involving recombinant DNA techniques to produce the claimed antibody.
- Claim 25: Pharmaceutical composition comprising the antibody with a carrier suitable for intravenous administration.
Claim Limitations
- The claims specify certain amino acid sequences (e.g., complementarity-determining regions).
- The composition claims include dosage forms and administration routes.
Patent Landscape Analysis
Related Patents
The scope of US 7,150,881 overlaps with several patents filed before and after its priority date (Jul 22, 2004).
- Key Prior Art: US Patent 6,994,943 (1999), relating to similar antibodies.
- Cited Prior Art: International and US patents focusing on specific antibody sequences and uses.
Patent Family and Territorial Coverage
- US Patent: Active until 2024, with potential extensions.
- EPO and WIPO filings: Filed under PCT in 2005, covering Europe, Asia, and other jurisdictions.
- Other regions: Several countries have filed equivalents, with varying claim scope.
Patent Litigation and Challenges
- No significant litigation records found involving this patent.
- Limited post-grant opposition or invalidation proceedings.
Landscape Trends
- Increasing filings in antibody therapeutics post-2000.
- Shift towards antibody fragments and bispecific antibodies.
- Growing filings focus on specific disease indications such as oncology and autoimmune disorders.
Market Implications
- Still relevant for biotech companies developing antibodies similar to the claimed sequences.
- Acts as a potential blocking patent for competitors working within the same antigen or disease target.
Summary of Patent and Claims Strategy
- The broad claims on antibody binding domains create a wide scope that could encompass various antibody formats.
- Narrower claims on specific sequences limit the patent's scope but strengthen validity.
- Continued patent filings have built a dense landscape around the key antibody target.
Key Takeaways
- US Patent 7,150,881 covers specific monoclonal antibody sequences, production methods, and formulations for therapeutic use.
- Its scope includes binding affinity to a defined antigen, with broader claims on antibody composition.
- The patent sits within an evolving landscape of therapeutic antibodies, with a focus on cancer and autoimmune disease targets.
- The patent's claims are both broad and specific, supporting both enforcement and innovation strategies.
- No significant legal challenges have been reported, maintaining its enforceability.
FAQs
Q1: Can this patent block other companies from developing similar antibodies targeting the same antigen?
A: Yes, if the antibody falls within the scope of the claims, it could prevent competitors from commercializing similar products without licensing.
Q2: How does the scope of this patent compare to newer antibody patents?
A: It has broader claims on antibody structure but may lack coverage of newer formats like bispecific or antibody-drug conjugates.
Q3: Are method claims protected as robustly as composition claims?
A: Composition claims tend to be broader; method claims are often narrower and easier to design around.
Q4: What strategies can competitors use to design around this patent?
A: Developing antibodies that bind to different epitopes or using alternative production methods can circumvent claim scope.
Q5: Does this patent cover all uses of the antibody in therapy?
A: No, it covers specific embodiments; other uses may require separate patent rights.
References
[1] United States Patent and Trademark Office. (2008). US Patent 7,150,881.
[2] WIPO. (2005). PCT Application WO2005108111.
[3] PatentScope. (2020). Patent family data and legal status.
[4] Hansch, C., & Leo, A. (2004). Exploring QSAR: Fundamentals and Applications.
(End of analysis.)
